Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative-Reference-Cited by-同舟云学术

Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative

Published:2015-08-28 Issue:5 Volume:171 Page:836-844
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bendapudi Pavan K.¹²,Li Ang²³,Hamdan Ayad²⁴,Uhl Lynne²⁵,Kaufman Richard²⁶,Stowell Christopher²⁷,Dzik Walter²⁷,Makar Robert S.²⁷

Affiliation:

1. Division of Hematology; Massachusetts General Hospital; Boston MA USA

2. Harvard Medical School; Boston MA USA

3. Department of Medicine; Massachusetts General Hospital; Boston MA USA

4. Division of Hematology and Oncology; Beth Israel Deaconess Medical Center; Boston MA USA

5. Department of Pathology; Beth Israel Deaconess Medical Center; Boston MA USA

6. Department of Pathology; Brigham and Women's Hospital; Boston MA USA

7. Blood Transfusion Service; Department of Pathology; Massachusetts General Hospital; Boston MA USA

Funder

Massachusetts General Hospital

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13658/fullpdf

Reference20 articles.

1. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature;Amorosi;Medicine,1966

2. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine;Bohm;British Journal of Haematology,2005

3. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura;Bukowski;Blood,1977

4. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience;Coppo;PLoS One,2010

5. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis;Furlan;Blood,1996

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Main features of ischemic stroke in patients with acute immune-mediated thrombotic thrombocytopenic purpura;Thrombosis Research;2024-09

2. Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency;Cureus;2024-08-18

3. ADAMTS13 in the New Era of TTP;International Journal of Molecular Sciences;2024-07-26

4. Analysis of clinical factors in first diagnosis of immune thrombotic thrombocytopenic purpura with report of 6 cases;2024-06-07

5. Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura;New England Journal of Medicine;2024-05-09